Notifications

Valeant shares close higher on details of earnings restatement

Valeant Pharmaceuticals shares got a positive bounce Tuesday after the company announced that its restatement of financial results for 2014 and 2015 involve just $58 million US of sales to Philidor were recognized at the wrong time.

Stock had plunged more than $25 in previous 3 sessions

Valeant shares had fallen more than $25 in the previous three trading sessions, including $12.84 on Monday amid news reports that a financial restatement was in the works. (Ryan Remiorz/Canadian Press)

Valeant Pharmaceuticals shares got a positive bounce Tuesday after the company announced that its restatement of financial results for 2014 and 2015 involve just $58 million US of sales to Philidor were recognized at the wrong time.

The Quebec-based company said late Monday that it should have recognized the revenue when the products were dispensed to patients, rather than when delivered to Philidor — an associated company that sold some Valeant drugs.

The stock closed at $109.40 on the Toronto Stock Exchange, a gain of $5.24, or 5.0 per cent, from Monday's close.

The stock had fallen more than $25 per share in the previous three sessions, including $12.84 on Monday amid news reports that a financial restatement was in the works.

Valeant said it estimates that its 2014 earnings will be reduced by 10 cents per share, in U.S. currency, and 2015 earnings will be increased by nine cents per share.

The amounts involved with the Philidor restatement are tiny compared with Valeant's total revenue and profit in 2014. It reported $8.3 billion US of revenue and $1.56 per share of earnings for the 12 months ended Dec. 31, 2014.

Selloff overdone

At least one analyst said the selloff was overdone, if it is based on concerns over the delayed release of fourth-quarter earnings as a result of the restatement.

"On an ongoing basis, we believe Philidor risk is mostly mitigated (except for potential penalties etc)," Douglas Miehm of RBC Capital Markets wrote in a report.

He said the successful implementation of a program with Walgreens to replace Philidor satisfies operational concerns. Walgreens is one of the biggest pharmacy retail chains in the United States.

Apart from the disruption caused by any financial restatement by a publicly traded company, Valeant is coping with a previous controversy that erupted last fall when questions were raised about its relationship with Philidor Rx Services.

Valeant's shares fell from $148.66 to $118.61 in heavy trading on Oct. 21. The stock has continued to trade below those levels and hit a 52-week intraday low of $69.33 US in New York on Nov. 18.

Valeant said on Oct. 30 that it had severed ties with the Pennsylvania-based online specialty pharmacy company after reviewing its practices. Philidor subsequently announced that it would cease operations.

Comments

To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.

By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.